Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Major Japanese Finance Firms Fund iPS Patent Company

This article was originally published in PharmAsia News

Executive Summary

To speed up the transfer of induced pluripotent stem cell technology to the pharmaceutical industry for new drug development, Kyoto University announced May 16 that the university in conjunction with Daiwa Securities Group, Mitsui Sumitomo Bank and NIFSMC Venture Capitals will establish a patent management company in June. The company will handle iPS-related patent issues such as: paying royalty to patent holders and licensing patents to regenerative medicine and pharmaceutical companies. The three firms agreed to invest ¥210 million and will increase their investment to ¥1.2 billion. Kyodo University will invest through an intermediary corporation set up by its executives and researchers. The director of research at the university, Hiroshi Matsumoto, commented that the company will prevent certain groups or companies from buying a controlling stake in the iPS patent. (Click here for more - Japanese language

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts